CANF
Can-Fite BioPharma Ltd.
$3.91
-0.72 (-15.55%)
At close · Jul 2
Market Cap
$8.38M
Shares
2,618,425
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.91
Open$4.34
Day$3.50–4.60
52W$2.56–21.00
Avg vol 30d2.8M
Short int47K · 1.8% float · 1.5d
Short vol35%
DataJan 2020–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Neutral
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−29% below
+
Price vs 50-day avg
+22% above
◦
RSI (14)
62 · neutral
+
MACD trend
positive
−
52-week position
7% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $3 › 200d $5 — 200d above 50d
+
Institutional flow
+1300% holders QoQ · +14 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
1.80% of float · ▼ -30.6% MoM · 1.5 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
14 holders — 13F breadth
Fundamentals
Fair
−
Revenue growth
−40% Y/Y
+
EPS growth
+45% Y/Y
−
Free cash flow
$-9.0M
+
Balance sheet
net cash $5.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−29% below
Bearish
Price vs 50-day avg
+22% above
Bullish
RSI (14)
62 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
7% · near low
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+1300% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.80% of float · ▼ -30.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $3
Now $4 · 7%
52-wk high $21
vs 200-day avg -29%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CANF
this stock
Can-Fite BioPharma Ltd.
|
$8.38M | -2.3% | -8.3% | — | 1.8% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CANF | +33.0% | +25.7% | -10.3% | +31.7% | -2.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +31.6% | +27.0% | -18.3% | +31.9% | -11.5% |